Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization

Oncogene

Volumn 29, Issue 9, 2010, Pages 1303-1315

  Sirvent, A ^a   Benistant C ^a   Pannequin, J ^a   Veracini, L ^a   Simon, V ^a   Bourgaux, J F ^b   Hollande, F ^a   Cruzalegui, F ^c   Roche, S ^a  

^a UNIV MONTPELLIER   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Colorectal cancer; Csk; Invasion; Oncogenic signalling; Tyrosine kinase Src

Indexed keywords

BINDING PROTEIN; GLYCOSPHINGOLIPID; PHOSPHOPROTEIN; PROTEIN TYROSINE KINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; COLON CANCER; CYTOPLASM; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

CELL MOVEMENT; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DOWN-REGULATION; HUMANS; MEMBRANE MICRODOMAINS; MEMBRANES; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; PROTEIN-TYROSINE KINASES; SRC-FAMILY KINASES;

EID: 77949262987     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.450     Document Type: Article

References (47)

1. Baumeister U, Funke R, Ebnet K, Vorschmitt H, Koch S, Vestweber D. (2005). Association of Csk to VE-cadherin and inhibition of cell proliferation. EMBO J 24: 1686-1695.
2. Benistant C, Bourgaux J, Chapuis H, Mottet N, Roche S, Bali J. (2001). The C-terminal Src kinase is a tumour antigen in human carcinoma. Cancer Res 61: 1415-1420.
3. Boggon TJ, Eck MJ. (2004). Structure and regulation of Src family kinases. Oncogene 23: 7918-7927.
4. Boureux A, Furstoss O, Simon V, Roche S. (2005). c-Abl tyrosine kinase regulates a Rac/JNK and a Rac/Nox pathway for DNA synthesis and c-myc expression induced by growth factors. J Cell Sci 118: 3717-3726.
5. Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, Angelisova P, et al. (2000). Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med 191: 1591-1604.
6. Cam WR, Masaki T, Shiratori Y, Kato N, Ikenoue T, Okamoto M, et al. (2001). Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma. Cancer 92: 61-70.
7. Causeret M, Taulet N, Comunale F, Favard C, Gauthier-Rouviere C. (2005). N-cadherin association with lipid rafts regulates its dynamic assembly at cell-cell junctions in C2C12 myoblasts. Mol Biol Cell 16: 2168-2180.
8. Collin G, Franco M, Simon V, Benistant C, Roche S. (2007). The Tom1L1-clathrin heavy chain complex regulates membrane partitioning of the tyrosine kinase Src required for mitogenic and transforming activities. Mol Cell Biol 27: 7631-7640.
9. Emaduddin M, Bicknell DC, Bodmer WF, Feller SM. (2008). Cell growth, global phosphotyrosine elevation, and c-Met phosphoryla-tion through Src family kinases in colorectal cancer cells. Proc Natl Acad Sci USA 105: 2358-2362.
10. Frame MC. (2004). Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 117: 989-998.
11. Horejsi V, Zhang W, Schraven B. (2004). Transmembrane adaptor proteins: organizers of immunoreceptor signalling. Nat Rev Immunol 4: 603-616.
12. Imamoto A, Soriano P. (1993). Disruption of the Csk gene, encoding a negative regulator of Src family tyrosine kinases, leads to neural tube defects and embryonic lethality in mice. Cell 73: 1117-1124.
13. Ingley E, Schneider JR, Payne CJ, McCarthy DJ, Harder KW, Hibbs ML, et al. (2006). Csk-binding protein mediates sequential enzymatic down-regulation and degradation of Lyn in erythropoietin-stimu-lated cells. J Biol Chem 281: 31920-31929.
14. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, et al. (1999). Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21: 187-190.
15. Ishizawar RC, Tice DA, Karaoli T, Parsons SJ. (2004). The C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism. J Biol Chem 279: 23773-23781.
16. Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, et al. (2000). Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 404: 999-1003.
17. Koegl M, Kypta RM, Bergman M, Alitalo K, Courtneidge SA. (1994). Rapid and efficient purification of Src homology 2 domain-containing proteins: Fyn, Csk and phosphatidylinositol 3-kinase p85. Biochem J 302: 737-744.
18. Kunte DP, Wali RK, Koetsier JL, Hart J, Kostjukova MN, Kilimnik AY, et al. (2005). Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation. FEBS Lett 579: 3497-3502.
19. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, et al. (2000). Constitutive and growth factor-regulated phosphor-ylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol 14: 1750-1775.
20. Leroy C, Fialin C, Sirvent A, Simon V, Urbach S, Poncet J, et al. (2009). Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates Src invasive activity in advanced colon carcinoma cells. Cancer Res 69: 2279-2286.
21. Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY. (2007). PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 282: 5413-5419.
22. Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, et al. (1997). Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15: 3083-3090. (Pubitemid 28043487)
23. Miyagi T, Wada T, Yamaguchi K. (2008). Roles of plasma membrane-associated sialidase NEU3 in human cancers. Biochim Biophys Acta 1780: 532-537.
24. Nada S, Yagi T, Takeda H, Tokunaga T, Nakagawa H, Ikawa Y, et al. (1993). Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 73: 1125-1135.
25. Nusrat A, Parkos CA, Verkade P, Foley CS, Liang TW, Innis-Whitehouse W, et al. (2000). Tight junctions are membrane microdomains. J Cell Sci 113: 1771-1781.
26. Oneyama C, Hikita T, Enya K, Dobenecker MW, Saito K, Nada S, et al. (2008). The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell 30: 426-436.
27. Pannequin J, Delaunay N, Buchert M, Surrel F, Bourgaux JF, Ryan J, et al. (2007). Beta-catenin/Tcf-4 inhibition after progastrin targeting reduces growth and drives differentiation of intestinal tumors. Gastroenterology 133: 1554-1568.
28. Read RD, Bach EA, Cagan RL. (2004). Drosophila C-terminal Src kinase negatively regulates organ growth and cell proliferation through inhibition of the Src, Jun N-terminal kinase, and STAT pathways. Mol Cell Biol 24: 6676-6689.
29. Resh MD. (1999). Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim Biophys Acta 1451: 1-16.
30. Saito K, Enya K, Oneyama C, Hikita T, Okada M. (2008). Proteomic identification of ZO-1/2 as a novel scaffold for Src/Csk regulatory circuit. Biochem Biophys Res Commun 366: 969-975.
31. Schaller MD, Parsons JT. (1995). pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk. Mol Cell Biol 15: 2635-2645.
32. Sirvent A, Boureux A, Simon V, Leroy C, Roche S. (2007). The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene 26: 7313-7323.
33. Smida M, Posevitz-Fejfar A, Horejsi V, Schraven B, Lindquist JA. (2007). A novel negative regulatory function of PAG: blocking Ras activation. Blood 110: 596-615.
34. Solheim SA, Torgersen KM, Tasken K, Berge T. (2008). Regulation of FynT function by dual domain docking on PAG/Cbp. J Biol Chem 283: 2773-2783.
35. Stewart RA, Li DM, Huang H, Xu T. (2003). A genetic screen for modifiers of the lats tumor suppressor gene identifies C-terminal Src kinase as a regulator of cell proliferation in Drosophila. Oncogene 22: 6436-6444.
36. Summy JM, Gallick GE. (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22: 337-358.
37. Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, et al. (2005). ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res 65: 1858-1867.
38. Tauzin S, Ding H, Khatib K, Ahmad I, Burdevet D, van Echten-Deckert G, et al. (2008). Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts. Blood 111: 2310-2320.
39. Thomas SM, Brugge JS. (1997). Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13: 513-609.
40. Veracini L, Franco M, Boureux A, Simon V, Roche S, Benistant C. (2006). Two distinct pools of Src family tyrosine kinases regulate PDGF-induced DNA synthesis and actin dorsal ruffles. J Cell Sci 20: 2921-2934.
41. Veracini L, Simon V, Richard V, Schraven B, Horejsi V, Roche S, et al. (2008). The Csk-binding protein PAG regulates PDGF-induced Src mitogenic signaling via GM1. J Cell Biol 182: 603-614.
42. Yeatman TJ. (2004). A renaissance for SRC. Nat Rev Cancer 4: 470-480.
43. Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, et al. (2004). Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell 13: 341-355.
44. Zhao M, Janas JA, Niki M, Pandolfi PP, Van Aelst L. (2006). Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis. Mol Cell Biol 26: 2479-2489.
45. Zheng X, Resnick RJ, Shalloway D. (2008). Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi. Int J Cancer 122: 1999-2007.
46. Zhu S, Bjorge JD, Cheng HC, Fujita DJ. (2008). Decreased CHK protein levels are associated with Src activation in colon cancer cells. Oncogene 27: 2027-2034.
47. Zhu S, Bjorge JD, Fujita DJ. (2007). PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res 67: 10129-10137.